anonymous
Guest
anonymous
Guest
If you don’t think they will be getting on formularies in 2025 you should be the 1st to go.AG takes over? WTF are you talking about. At its peak, it may get 5% share. And that share is at the expense of Farxiga.
if you’re letting the AG win in your territory, you should be 1st to go. Replace with a displaced respiratory or biosimilar rep.